Mollugin suppresses bladder cancer through parkin-associated mitophagy inhibition and immunogenic tumor microenvironment remodeling

Background Bladder cancer remains a prevalent malignancy characterized by frequent recurrence, therapeutic resistance and limited durable responses tocurrent treatment strategies. Mollugin (Mol), a natural bioactive compound withreported antitumor activity, has not been fully characterized in bladder cancer. Methods MB49 mouse bladder cancer cells were treated with different concentrations of Mol. Transcriptomic profiling was performed to identify Molregulated biological pathways and provide mechanistic guidance for subsequent validation. ROS accumulation, cell viability, cytoskeletal alterations, mitochondrial membrane potential and ICD-associated markers were evaluated using fluorescence-based assays. Mitophagy-associated alterations were assessed by LC3/TOMM20 immunofluorescence and western blot analysis of PINK1, Parkin, HSP60, VDAC1 and TOMM20. Parkin knockdown was performed to determine the contribution of Parkin-associated mitophagy to Mol-induced cellular injury. The antitumor effects of Mol, alone or combined with systemic anti-PD-1 blockade, were evaluated in a syngeneic mouse bladder cancer model. Tumorinfiltrating T cells and macrophage phenotypes were analyzed by flow cytometry. Results Mol induced ROS accumulation, reduced cell viability and included JNK/p38 phosphorylation in MB49 bladder cancer cells in a concentration-dependent manner. Transcriptomic analysis revealed distinct gene expression profiles between PBS- and Mol-treated cells and identified enrichment of mitophagy, apoptosis, NF-κB, PI3K-Akt, MAPK and cancer-related signaling pathways. Mol reduced mitochondrial membrane potential-associated fluorescence and induced ICD-associated DAMP changes, including increased cellular CRT immunoreactivity, reduced intracellular HMGB1 staining, and increased extracellular ATP and HMGB1 levels. Mechanistically, Mol suppressed PINK1/Parkin-associated mitophagy, as demonstrated by reduced PINK1 and Parkin expression, decreased LC3–TOMM20 co-localization and accumulation of mitochondrial stress-associated proteins including HSP60, VDAC1 and TOMM20. Parkin silencing further enhanced Mol-induced ROS accumulation and cell death, supporting a protective role of Parkin-associated mitophagy in tumor cells. In vivo, Mol suppressed tumor growth, reduced tumor cell proliferation, increased tumor cell death and remodeled the tumor immune microenvironment, characterized by altered tumor-associated macrophage phenotypes and increased CD8-positive T-cell infiltration. Combination with systemic anti-PD-1 blockade further enhanced these immune-associated changes. Conclusion Mol suppresses bladder cancer by inhibiting Parkin-associated mitophagy and inducing immunogenic tumor microenvironment remodeling. These findings reveal a link between mitochondrial quality control, ICDassociated tumor injury and immune regulation, supporting Mol as a potential mitochondria-targeted and immunomodulatory therapeutic candidate for bladder cancer.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1999992
Primary Topic
Autophagy in Disease and Therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mollugin suppresses bladder cancer through parkin-associated mitophagy inhibition and immunogenic tumor microenvironment remodeling

Huizhi Wei, Shuaijun Ma, Xiang Ren, Tong Xu et al.
2 links
Frontiers in Immunology
Autophagy in Disease and Therapy
article

Mollugin suppresses bladder cancer through parkin-associated mitophagy inhibition and immunogenic tumor microenvironment remodeling

Huizhi Wei, Shuaijun Ma, Xiang Ren, Tong Xu, Xiaoyan Zhang, Guohui Wang, Xiaojian Yang, Shichao Han, Yan Li
article en

Abstract

Background Bladder cancer remains a prevalent malignancy characterized by frequent recurrence, therapeutic resistance and limited durable responses tocurrent treatment strategies. Mollugin (Mol), a natural bioactive compound withreported antitumor activity, has not been fully characterized in bladder cancer. Methods MB49 mouse bladder cancer cells were treated with different concentrations of Mol. Transcriptomic profiling was performed to identify Molregulated biological pathways and provide mechanistic guidance for subsequent validation. ROS accumulation, cell viability, cytoskeletal alterations, mitochondrial membrane potential and ICD-associated markers were evaluated using fluorescence-based assays. Mitophagy-associated alterations were assessed by LC3/TOMM20 immunofluorescence and western blot analysis of PINK1, Parkin, HSP60, VDAC1 and TOMM20. Parkin knockdown was performed to determine the contribution of Parkin-associated mitophagy to Mol-induced cellular injury. The antitumor effects of Mol, alone or combined with systemic anti-PD-1 blockade, were evaluated in a syngeneic mouse bladder cancer model. Tumorinfiltrating T cells and macrophage phenotypes were analyzed by flow cytometry. Results Mol induced ROS accumulation, reduced cell viability and included JNK/p38 phosphorylation in MB49 bladder cancer cells in a concentration-dependent manner. Transcriptomic analysis revealed distinct gene expression profiles between PBS- and Mol-treated cells and identified enrichment of mitophagy, apoptosis, NF-κB, PI3K-Akt, MAPK and cancer-related signaling pathways. Mol reduced mitochondrial membrane potential-associated fluorescence and induced ICD-associated DAMP changes, including increased cellular CRT immunoreactivity, reduced intracellular HMGB1 staining, and increased extracellular ATP and HMGB1 levels. Mechanistically, Mol suppressed PINK1/Parkin-associated mitophagy, as demonstrated by reduced PINK1 and Parkin expression, decreased LC3–TOMM20 co-localization and accumulation of mitochondrial stress-associated proteins including HSP60, VDAC1 and TOMM20. Parkin silencing further enhanced Mol-induced ROS accumulation and cell death, supporting a protective role of Parkin-associated mitophagy in tumor cells. In vivo, Mol suppressed tumor growth, reduced tumor cell proliferation, increased tumor cell death and remodeled the tumor immune microenvironment, characterized by altered tumor-associated macrophage phenotypes and increased CD8-positive T-cell infiltration. Combination with systemic anti-PD-1 blockade further enhanced these immune-associated changes. Conclusion Mol suppresses bladder cancer by inhibiting Parkin-associated mitophagy and inducing immunogenic tumor microenvironment remodeling. These findings reveal a link between mitochondrial quality control, ICDassociated tumor injury and immune regulation, supporting Mol as a potential mitochondria-targeted and immunomodulatory therapeutic candidate for bladder cancer.

Frontiers in ImmunologyVol. 17
Shanxi University (CN), Shanxi University of Traditional Chinese Medicine (CN), Xijing Hospital (CN), Air Force Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Autophagy in Disease and Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon